Home › Trial NCT04522908
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
- Trial IDNCT04522908
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Enrollment40
- Start date2020-10-12
- ConditionsHepatocellular Carcinoma (HCC) · Second Line Treatment
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.